Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 5/20 | 0.59 |
| ▸ | ESR1 | P03372 | 4/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | PGR | P06401 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.55 |
| ▸ | AR | P10275 | 3/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11861930 | 0.88 | PGR (0.46) | CYP2C19ESR1SLC6A2SLC6A4CHRM2 | |
| Bolandiol Dipropionate SCHEMBL30875871 | 0.80 | MAPT (0.57) | CYP2C19ESR1SLC6A2LMNAPGR | |
| Bolandiol Dipropionate SCHEMBL634970 | 0.80 | MAPT (0.57) | CYP2C19ESR1SLC6A2LMNAPGR | |
| SCHEMBL11857339 | 0.79 | PGR (0.55) | CYP2C19ESR1SLC6A2SLC6A4CHRM2 | |
| SCHEMBL4706366 | 0.77 | CYP2C19 (0.63) | CYP2C19ESR1SLC6A2SLC6A4CHRM2 | |
| Norethandrolone SCHEMBL23801611 | 0.76 | LMNA (0.71) | CYP2C19ESR1SLC6A2SLC6A4CHRM2 | |
| Norethandrolone SCHEMBL147638 | 0.76 | LMNA (0.71) | CYP2C19ESR1SLC6A2SLC6A4CHRM2 | |
| Ethylestrenol SCHEMBL11217999 | 0.74 | SLC6A4 (1.00) | CYP2C19ESR1SLC6A2SLC6A4CHRM2 | |
| Ethylestrenol SCHEMBL147908 | 0.74 | SLC6A4 (1.00) | CYP2C19ESR1SLC6A2SLC6A4CHRM2 | |
| SCHEMBL8424688 | 0.73 | PGR (0.62) | CYP2C19ESR1SLC6A2SLC6A4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-4631960-A1 | PEPTIDE HAVING INHIBITORY ACTIVITY AGAINST OSTEOCLAST DIFFERENTIATION, AND USE THEREOF | Caregen Co., Ltd. (KR) | 2025-10-15 | — | — | EP | disclosed |
| US-12440479-B2 | Prevention or treatment of chronic organ injury | GEORG-AUGUST-UNIVERSITAET GOETTINGEN, STIFTUNG OEFFENTLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2025-10-14 | — | — | US | disclosed |
| US-20250297020-A1 | RANK-L BINDING MOLECULES | ADALTA LIMITED (AU) | 2025-09-25 | — | — | US | disclosed |
| US-20250281509-A1 | SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSTY | 2025-09-11 | — | — | US | disclosed |
| CN-119700747-B | Application of matrine A in preparation of product for preventing and treating osteoporosis | 云南农业大学 | 2025-05-06 | — | — | CN | disclosed |
| CN-119909054-A | Application of beta-hydroxybutyric acid in preparation of medicine for preventing and/or treating osteoporosis | 西南医科大学附属医院 | 2025-05-02 | — | — | CN | disclosed |
| CN-119700747-A | Application of matrine A in preparation of product for preventing and treating osteoporosis | 云南农业大学 | 2025-03-28 | — | — | CN | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CYP2C19 4871/4885ESR1 2252/4885SLC6A2 2841/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | CYP2C19 4768/4885ESR1 1133/4885SLC6A2 3073/4885 |
| US-12440479-B2 | Prevention or treatment of chronic organ injury | FKBP2, DUSP3, FKBP1A | CYP2C19 4786/4885ESR1 4535/4885SLC6A2 2383/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CYP2C19 4874/4885ESR1 2385/4885SLC6A2 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.